type 2 diabetes
Conditions
Interventions
Administer GLP-1 receptor agonist (Exenatide) 1. In principle, this drug is administered within 60 minutes before morning supper and not after meals. 2. The administration of this drug starts with
Sponsors
Kagawa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with type 2 diabetes who meet the criteria below 1) HbA1c (NGSP): 7.0% or more and less than 10% 2) Patients aged 20 years or older and less than 80 years regardless of gender 3) Diabetic nephropathy stage 2-3 (diagnostic criteria attached) 4) Patients who can obtain written consent to participate in this clinical research
Exclusion criteria
Exclusion criteria: Patients who fall under any of the following are excluded from this clinical study. 1) Patients who fall under the contraindication for GLP-1 receptor agonist 2) Patients participating in other clinical research 3) Pregnant women, pregnant women, lactating women or women who may have pregnancy 4) Patients with other serious complications 5) Patients judged to be unsuitable as a target by the judgment of other doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of change of delta eGFR at 12 weeks before and after administration | — |
Countries
Japan
Contacts
Public ContactKensaku Fukunaga
Kagawa University Hospital Department of Endocrinology and Metabolism
Outcome results
None listed